We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Induction Related BK Viremia in Renal Transplant Patients (BK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00610961
Recruitment Status : Completed
First Posted : February 8, 2008
Last Update Posted : September 27, 2011
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The increase immunosuppression in our transplant population has led to an unacceptable rate of patients at risk for BK virus nephropathy. Reducing induction immunosuppression by switching from Thymoglobulin to Simulect will reduce the incidence of serum positivity for BK by PCR.

Condition or disease Phase
Disease Due to BK Polyomavirus Transplantation Infection Disorder Related to Transplantation Phase 4

Detailed Description:

Our standard of care has been changed from Thymoglobulin to Simulect and now patients were enrolled in this observational trial to gather data on their outcomes related to BK viremia and rejection rates. Two groups of patients were compared.

Retrospective (historical or control) group of subjects: patients who had received a kidney transplant and were inducted with Thymoglobulin prior to study initiation.

Prospective group of subjects: patients who is scheduled to receive kidney transplant and will be inducted with Simulect (Basiliximab).

Inductions in both groups was/is Standard of Care at a time of treatment.


Study Design

Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case Control
Official Title: The Induction Agent Effect on BK Viremia in Renal and Pancreas Transplant Patients
Study Start Date : October 2007
Primary Completion Date : April 2009
Study Completion Date : November 2009
Groups and Cohorts

Group/Cohort
Basiliximab (Simulect) Induction
Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
Thymoglobulin Induction
Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.


Outcome Measures

Primary Outcome Measures :
  1. BK Virus Viremia titer, >400 copies by Polymerase Chain Reaction (PCR) [ Time Frame: One year ]
    BKVV (BK Visus Viremia) titer is measured by PCR at 1, 3,6,9 and 12 month time points.


Secondary Outcome Measures :
  1. Incidence of Acute Rejection of Transplanted Kidney [ Time Frame: One year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
de novo renal or renal/pancrease transplant patients
Criteria

Inclusion Criteria:

  • De novo transplant
  • Aged 18-75

Exclusion Criteria:

  • Serious medical condition which, in the opinion of the Principal Investigator, might interfere with the subject's ability to successfully complete the protocol.
  • Any medical condition which, in the opinion of the Principal Investigator, might compromise the safety of the subject in participating in the protocol
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00610961


Locations
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
Novartis Pharmaceuticals
Investigators
Principal Investigator: Herwig-Ulf Meier-Kriesche, MD University of Florida
More Information

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT00610961     History of Changes
Other Study ID Numbers: 20071016
First Posted: February 8, 2008    Key Record Dates
Last Update Posted: September 27, 2011
Last Verified: September 2011

Keywords provided by University of Florida:
BK Polyomavirus
Transplantation, Kidney
Transplantation, Pancreas

Additional relevant MeSH terms:
Viremia
Virus Diseases
Sepsis
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Thymoglobulin
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents